LakeShore Biopharma (LSB) AI Stock Analysis

• Market Cap: $15.87M
• Dividend Yield: N/A
• Average Volume (3M): 76.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 758
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 41,212,692
• 10 Day Avg. Volume: 153,156
• 30 Day Avg. Volume: 76,270
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: 42.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $0.50 ▼(-28.57% Downside)

LakeShore Biopharma's overall stock score is primarily impacted by its weak financial performance and technical indicators. The company's persistent losses and negative cash flows are significant concerns, compounded by bearish technical signals. The lack of profitability and dividend yield further detracts from its valuation appeal, making it a high-risk investment.

LakeShore Biopharma Business Overview & Revenue Model

Company Description

LakeShore Biopharma (LSB) is a leading biotechnology firm specializing in the research, development, and commercialization of innovative therapeutic solutions in the fields of oncology and autoimmune diseases. The company leverages advanced biopharmaceutical technologies to create novel drug candidates aimed at improving patient outcomes. LSB's portfolio includes a range of biologics and small molecule therapies, with a strong emphasis on precision medicine and personalized treatment regimens.

How the Company Makes Money

LakeShore Biopharma generates revenue primarily through the commercialization of its therapeutic products, which include sales of approved drugs and biologics. The company also engages in strategic partnerships and collaborations with larger pharmaceutical companies for co-development and licensing agreements, which provide significant upfront payments and ongoing royalties based on product sales. Additionally, LSB may receive funding through government grants and research contracts aimed at advancing its clinical trials and product development efforts. The combination of direct product sales, royalties from partnerships, and external funding sources contributes to LSB's overall revenue stream.

LakeShore Biopharma Financial Statement Overview

Summary

LakeShore Biopharma exhibits strong gross profit margins, but persistent losses and negative cash flows pose significant challenges. The company needs to focus on improving operational efficiency and profitability to enhance its financial health. While leverage management has improved, further efforts are required to stabilize cash flows and achieve sustainable growth.

Income Statement

LakeShore Biopharma shows a consistent gross profit margin above 75%, indicating strong product profitability. However, the company faces challenges with negative net profit margins and EBIT margins, reflecting ongoing losses. Revenue growth is positive, but the company needs to address its high operating losses to improve overall profitability.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management, yet it remains relatively high. The negative return on equity highlights ongoing profitability challenges. The equity ratio suggests a moderate reliance on equity financing, but the company needs to enhance its asset utilization and profitability.

Cash Flow

LakeShore Biopharma's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is positive, indicating some efficiency in converting net income to cash, but the overall negative cash flow growth and coverage ratios highlight liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	577.33M	614.96M	573.42M	687.20M	502.95M	257.02M
Gross Profit	389.12M	507.19M	455.73M	533.84M	385.88M	197.36M
EBITDA	-315.55M	-48.54M	-368.66M	-76.80M	-67.20M	-116.78M
Net Income	-436.09M	-99.98M	-433.46M	-145.48M	-545.73K	-191.83M
Balance Sheet
Total Assets	1.51B	1.37B	1.51B	1.72B	201.03M	91.37K
Cash, Cash Equivalents and Short-Term Investments	246.35M	28.08M	246.35M	370.11M	885.20K	390.46M
Total Debt	424.46M	414.40M	424.46M	498.63M	380.59M	5.01K
Total Liabilities	927.82M	867.91M	927.82M	991.30M	20.35M	70.01K
Stockholders Equity	585.21M	499.75M	585.21M	728.45M	180.68M	21.36K
Cash Flow
Free Cash Flow	0.00	-138.84M	-339.48M	-239.52M	-299.55M	-351.49M
Operating Cash Flow	0.00	-120.98M	-295.23M	-182.47M	-613.23K	-246.61M
Investing Cash Flow	0.00	-17.01M	-44.25M	-56.98M	-200.00M	-104.24M
Financing Cash Flow	0.00	-3.58M	205.26M	317.45M	201.50M	739.26M

LakeShore Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSB, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.82, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.96 is Neutral, neither overbought nor oversold. The STOCH value of 49.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSB.

LakeShore Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	51 Neutral	$100.15M	-33.55	-16.54%	―	202.41%	98.99%
HOWL	48 Neutral	$94.89M	-1.26	-96.08%	―	-100.00%	-22.09%
CASI	46 Neutral	$24.48M	-0.52	-2120.91%	―	41.43%	-50.12%
NRXP	45 Neutral	$71.07M	-1.34	―	―	―	18.51%
LSB	38 Underperform	$15.87M	―	-74.07%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

LakeShore Biopharma Corporate Events

LakeShore Biopharma Transitions to OTC Market Post-Delisting

On September 22, 2025, LakeShore Biopharma announced its transition from the Nasdaq Capital Market to the OTC Pink Open Market following a delisting determination due to non-compliance with Nasdaq’s minimum bid price requirement. This move does not affect the company’s business operations, and it remains committed to transparency with its stakeholders.

LakeShore Biopharma Faces Nasdaq Delisting Over Bid Price Rule Non-Compliance

On September 12, 2025, LakeShore Biopharma announced it received a delisting determination letter from Nasdaq due to non-compliance with the Bid Price Rule, as its share price remained below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period due to a reverse stock split conducted on October 1, 2024. Nasdaq plans to delist the company’s securities unless an appeal is requested by September 18, 2025. LakeShore Biopharma is evaluating its options, including the possibility of appealing the decision.

LakeShore Biopharma Appoints Advisors for Proposal Review

On September 10, 2025, LakeShore Biopharma announced the appointment of Kroll, LLC as its financial advisor and Gibson, Dunn & Crutcher LLP along with Maples and Calder (Hong Kong) LLP as legal counsel to its Special Committee. This committee is tasked with evaluating a revised preliminary non-binding proposal dated August 26, 2025. The company has cautioned shareholders that no decisions have been made regarding the proposal, and there is no assurance of a definitive offer or agreement. This move underscores LakeShore Biopharma’s strategic approach to navigating potential transactions, reflecting its commitment to thorough evaluation and due diligence.

LakeShore Biopharma Receives Revised Acquisition Proposal from Consortium

On August 28, 2025, LakeShore Biopharma announced the receipt of a revised preliminary non-binding proposal from a consortium led by Oceanpine Capital to acquire all outstanding ordinary shares not owned by the consortium. The proposal, which maintains the original offer price of US$0.86 per share, led to the formation of a special committee to evaluate the offer. The consortium, owning 52.1% of the company’s shares, has agreed to support the transaction, but the board has yet to make a decision, leaving the outcome uncertain.

LakeShore Biopharma Receives Acquisition Proposal from Oceanpine Capital

On August 18, 2025, LakeShore Biopharma announced that it received a preliminary non-binding proposal from Oceanpine Capital to acquire all outstanding ordinary shares not owned by Oceanpine Capital for $0.86 per share, representing a premium over recent trading prices. The board of directors will review the proposal to determine the best course of action for the company and its shareholders. The proposal is not subject to a financing condition, and Oceanpine Capital intends to fund the transaction with available cash and rollover equity.

LakeShore Biopharma Reports FY2025 Financial Results with Improved Profitability

LakeShore Biopharma announced its financial results for the fiscal year ended March 31, 2025, highlighting a 7.2% increase in total revenue to RMB615.0 million and an 11.3% rise in gross profit to RMB507.2 million. Despite not meeting revenue and adjusted EBITDA guidance, the company significantly improved its financial performance compared to the previous year, narrowing its net loss by 77%. The company faced challenges such as intensified competition in the rabies vaccine market and ongoing litigation affecting its financial flexibility. Looking forward, LakeShore plans to enhance its market position by expanding its rabies vaccine coverage, advancing clinical trials, and improving operational efficiency.

LakeShore Biopharma Announces Change in Control Following Private Placement

On July 8, 2025, LakeShore Biopharma Co., Ltd underwent a significant change in control when it entered into a Share and Warrant Purchase Agreement with Crystal Peak Investment Inc. This agreement involved the sale of 16,987,542 ordinary shares and warrants for an additional 16,987,542 shares, amounting to a total purchase price of $15 million. The transaction resulted in Crystal Investment acquiring a controlling 51% stake in the company, marking a pivotal shift in ownership and potentially impacting the company’s strategic direction and market positioning.

LakeShore Biopharma Secures $15 Million in Private Placement Financing

On July 8, 2025, LakeShore Biopharma Co., Ltd announced a US$15 million private placement financing through a share and warrant purchase agreement with an institutional investor. This strategic move is expected to bolster the company’s financial position, potentially enhancing its capacity to advance its product development and strengthen its market presence in the biopharmaceutical industry.